the compounds are great tools for binding receptors and stabilizing them for cr ystallization and might be useful for bootstrapping structures to develop new drugs.
"Having t heir help in accessing and generating compounds that are going to bind to the receptors and analyzing the data associated with that binding event is probably the most important aspect of what pharma is bringing to the collaboration," he said.
Lessons learned
Stevens told SciBX that a major stimulus for the new collaboration was the termination of funding for the Protein Structure Initiative (PSI) by the NIH's National Institute of General Medical Sciences earlier this year. According to an NIH press release, the initiative was discontinued after an external review committee concluded that, despite the gains made since PSI was founded in 2000, the resources, products and results were "underutilized by the broader scientific community."
PSI was originally formed to develop and use high throughput screening systems to solve 3D atomic-level structures of proteins and make them easily obtainable by the scientific community. The program involved multicenter collaborative studies and produced more than 6,300 protein structures and 400 technologies and methods to streamline the process of structure determination.
Stevens was the principal investigator from The Scripps Research Institute who formed the GPCR Network, a collaborative program funded by PSI to understand GPCR structure and function. He told SciBX that the GPCR structures obtained in the PSI program were viewed as useful but the PSI program was controversial because it was less hypothesis-driven research than the National Institute of General Medical Sciences is currently funding.
He added that for some of the leading academic groups in the field of GPCR structural biology research, the only solution to the cut in PSI funding was to work more closely with industry. By allowing the pharmas to select the targets and collaborate on the science, the consortium hopes to generate data that is more therapeutically useful, he told SciBX.
In putting together the GPCR Consortium, Stevens used the setup of the Structural Genomics Consortium (SGC) as a template with assistance from Aled Edwards, director and CEO of the SGC.
"That model worked really well, particularly for kinases and epigenetics," said Stevens. "Before, labs were solving structures of a few kinases here and there, but the SGC did it in an organized fashion and did an incredible job of opening up the kinase knowledge base."
"Having their help in accessing and generating compounds that are going to bind to the receptors and analyzing the data associated with that binding event is probably the most important aspect of what pharma is bringing to the collaboration." The GPCR Consortium will also deposit its data in the Protein Data Bank.
Like the SGC, the GPCR Consortium will rely on international collaboration between academic centers that have different strengths and skill sets.
Stevens said, "In terms of novel technologies, in China we will be doing a lot of the in vitro stability screening and signaling assays, and in the U.S. we have access to a new technology called the free electron laser that is able to use much smaller crystals." He also noted that the technology to obtain protein structures has advanced significantly in the last decade, which has lowered the cost and shortened the time it takes to generate structural data.
Hanson added that acquiring the data is just the first step. Industry funding would also be used for organizing and sharing the data so that it can be used more effectively by the pharma partners and the larger biomedical community, he said.
The importance of data management was a lesson learned from the genomics field, which also dealt with vast amounts of data, he said. "It's very analogous to the Human Genome Project, where academia had their effort and industry had their effort," which led to a lot of expense, inefficiency and a cottage industry of small labs engaged in redundant efforts.
"What we are trying to do is take it a step further and evolve, so instead of competing we are working together to collect this information," Stevens said.
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GPCRs are divided into five major families: rhodopsin, secretin, adhesion, glutamate and frizzled/taste receptor type 2 (TAS2R; T2R).
Receptors with solved structures in the dendrogram include: adenosine A 2A receptor (ADORA 2A ), adrenergic receptor b1 (ADRB1), ADRB2, CC chemokine receptor 5 (CCR5; CD195), muscarinic acetylcholine receptor M2 (CHRM2; HM2), CHRM3 (HM3), corticotropin-releasing factor receptor 1 (CRHR1; CRFR1), CXC chemokine receptor 1 (CXCR1), CXCR4 (NPY3R), dopamine D3 receptor (DRD3), glucagon receptor (GCGR), metabotropic glutamate receptor subtype 1 (mGluR1; GRM1), histamine H1 receptor (HRH1), serotonin (5-HT 1B ) receptor (HTR1B), HTR2B, neurotensin receptor 1 (NTSR1), opioid receptor d1 (OPRD1; DOR), k-opioid receptor (OPRK1; KOR), opiate receptor-like 1 (OPRL1), m-opioid receptor (OPRM1; MOR), protease-activated receptor 1 (PAR1), purinergic receptor P2Y G protein-coupled 12 (P2RY12; P2Y12), rhodopsin (RHO; OPN2), smoothened (SMO), sphingosine 1-phosphate receptor 1 (S1PR1; S1P1; EDG1).
Not shown: free fatty acid receptor 1 (FFAR1; GPR40). ( 
